Unyvero Pneumonia Application

Pneumonia is a severe, life-threatening, acute infection of the lower respiratory tract. It has various causes. Pneumonia is most frequently caused by bacteria and viruses. It is a rapidly advancing condition with a mortality rate of up to 36% and an average hospital stay of 11–14 days.

The guidelines of the American Thoracic Society / Infectious Disease Society of America differentiate between the following types of pneumonia:

  • Community-acquired pneumonia (CAP)
  • Hospital-acquired pneumonia (HAP)
  • Ventilator-associated pneumonia (VAP)
  • Healthcare-associated pneumonia (hCAP)

In order to fundamentally improve treatment quality in pneumonia cases, reliably identifying the causative pathogens at an early stage is just as important as adequate antimicrobial treatment.

Studies have shown that the medical result in cases of hCAP, HAP and VAP can significantly benefit from faster diagnosis.

Working with clinical partners, a prospective clinical study of the Unyvero System and the Unyvero P50 Pneumonia Cartridge has been successfully concluded in the European Union. Further clinical studies are currently underway for clinical evaluation with the Unyvero Pneumonia Application in Germany, Austria, Switzerland and Europe.

Additionally, a multicenter, prospective FDA approval study is approved in the United States for the pneumonia application, which is called "LRT" in the United States.